Organon & Co. Overview
Pro stress-test →Organon is a global healthcare company focused on women's health, biosimilars and established medicines, with 70+ products in over 140 markets. The company reported 2025 sales of US$1,507 million in Q4 with a net loss of US$205 million, guiding to about US$6.2 billion in 2026 revenue.
Strategic Profile
Pro stress-test →Organon's women's health and biosimilar portfolios are positioned to offset pressure on older, off-patent brands and gradually restore margins. The company recently received FDA approval for extended duration use of NEXPLANON with a new REMS safety program. In January 2026, Organon became a potential acquisition target when Sun Pharmaceutical Industries submitted a non-binding proposal to acquire the company.
Competitive Landscape
Pro stress-test →Organon faces competition from larger pharma peers including Eli Lilly (which reported 42.6% revenue growth) and Bristol-Myers Squibb (1.4% growth). The company's smaller scale and legacy portfolio position it at a disadvantage versus larger innovators, though its women's health and biosimilars focus targets underserved niches.
Industry Context
Organon & Co. operates in Pharmaceuticals & Biotech.
Key facts
Founded: 2021 · Headquarters: Jersey City, New Jersey · Revenue: $6.2B · Market cap: $1.9B